Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2501002 | 1.00 | HCRTR1 (0.61) | HCRTR1HCRTR2 | |
| SCHEMBL2502197 | 0.91 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL2494064 | 0.91 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL2494454 | 0.86 | HCRTR1 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL2494268 | 0.86 | HCRTR1 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL2518898 | 0.84 | HCRTR1 (0.61) | HCRTR1HCRTR2 | |
| SCHEMBL2497343 | 0.84 | HCRTR1 (0.71) | HCRTR1HCRTR2 | |
| SCHEMBL2503733 | 0.84 | HCRTR1 (0.71) | HCRTR1HCRTR2 | |
| SCHEMBL2500315 | 0.84 | HCRTR1 (0.61) | HCRTR1HCRTR2 | |
| SCHEMBL2495460 | 0.83 | HCRTR1 (0.56) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150115-B1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2150115-B1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8030495-B2 | Cyclopropyl pyrrolidine orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2011-10-04 | — | — | US | disclosed |
| US-8030495-B2 | Cyclopropyl pyrrolidine orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2011-10-04 | — | — | US | disclosed |
| US-8030495-B2 | Cyclopropyl pyrrolidine orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2011-10-04 | — | — | US | disclosed |
| US-20100152191-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-06-17 | — | — | US | disclosed |
| US-20100152191-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-06-17 | — | — | US | disclosed |
| US-20100152191-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-06-17 | — | — | US | disclosed |
| WO-2008150364-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152191-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, OXTR | HCRTR1 1/4885HCRTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.